XOMA CORP | 3,163 Euro | +0,108 +3,54 % | |
| WKN: A1JR93 ISIN: US98419J1079 Ticker-Symbol: X0M | Stuttgart | 24.05.13 | 08:09 Uhr |
Branche BiotechnologieAktienmarkt NASDAQ Biotech |
|
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 14.05. | Shares of XOMA Rise Above Previous 52-Week High | 5 | SmarTrend | |
| 13.05. | Traders Get Bullish on Shares of XOMA, Shares Up 5.5% | 9 | SmarTrend | |
| 13.05. | XOMA Looks to Continue to Trade Above its Annual-High Share Price Today | 1 | SmarTrend | |
| 10.05. | XOMA Management Presents at Credit Suisse 2013 Antibody Day (Transcript) | 8 | Seeking Alpha | |
| 09.05. | Ladenburg hebt das Kursziel für XOMA von $5 auf $6. | 154 | BörseGo | |
| Ladenburg hebt das Kursziel für XOMA von $5 auf $6.
(© BörseGo AG 2013 - Autor: Simon Hauser, Redakteur) Mehr lesen zu: Ladenburg hebt das Kursziel für XOMA von $5 auf $6. | ||||
| 09.05. | Upgrade Alert for XOMA | 25 | SmarTrend | |
| 09.05. | XOMA Corp CEO Discuses Q1 2013 Results - Earnings Call Transcript | 16 | Seeking Alpha | |
| 10.04. | XOMA Says Study Investigating Gevokizumab Opened for Enrollment | 12 | Benzinga.com | |
| 19.03. | FDA's New "Breakthrough" Designation Allows New Drugs to Gain Approval after Just 1 Round of Testing / Five Star Equities Provides Stock Research on Oncolytics Biotech and XOMA | 102 | Marketwired | |
| NEW YORK, NY -- (Marketwire) -- 03/19/13 -- Programs developed by the U.S. Food and Drug Administration to speed up the approval process has been a major driver for growth within the Biotech Industry.... Mehr lesen zu: FDA's New "Breakthrough" Designation Allows New Drugs to Gain Approval after Just 1 Round of Testing / Five Star Equities Provides Stock Research on Oncolytics Biotech and XOMA | ||||
| 18.03. | Xoma hires Genentech, Roche veteran as chief commercial officer | 31 | bizjournals | |
| 14.03. | XOMA Posts Narrower Loss | 20 | Zacks | |
| 13.03. | XOMA's CEO Discusses Q4 2012 Results - Earnings Call Transcript | 13 | Seeking Alpha | |
| 28.02. | Traders Get Bullish on Shares of XOMA, Shares Up 6.8% | 13 | SmarTrend | |
| 26.02. | Sharp Increase in FDA Drug Approvals a Major Factor in Biotech Industry's Success / RDInvesting Provides Stocks Research on XOMA and EntreMed | 52 | Marketwired | |
| NEW YORK, NY -- (Marketwire) -- 02/26/13 -- A sharp increase in drug approvals and mergers and acquisitions combined to create a bull market for the Biotechnology Industry in 2012. The iShares NASDAQ... Mehr lesen zu: Sharp Increase in FDA Drug Approvals a Major Factor in Biotech Industry's Success / RDInvesting Provides Stocks Research on XOMA and EntreMed | ||||
| 29.01. | Major Revenue Losses From Patent Expirations Forces Big Pharma Companies to Look to the Biotech Industry for Replacements / Five Star Equities Provides Stock Research on Sunesis Pharmaceuticals and XOMA | 71 | Marketwired | |
| NEW YORK, NY -- (Marketwire) -- 01/29/13 -- Lost revenues from expiring patents has played a major part in the Biotech Industry's success in recent years. A total of 676 takeovers of biotechnology... Mehr lesen zu: Major Revenue Losses From Patent Expirations Forces Big Pharma Companies to Look to the Biotech Industry for Replacements / Five Star Equities Provides Stock Research on Sunesis Pharmaceuticals and XOMA | ||||
| 16.01. | Xoma: Will The Love-Hate Marriage With Investors End Up In A Stable Relationship? | 11 | Seeking Alpha | |
| 16.01. | XOMA: Will The Love-Hate Marriage With Investors Finally End Up In A Stable Relationship? | 4 | Seeking Alpha | |
| 14.01. | XOMA's Gevokizumab Study Update | 10 | Zacks | |
| 07.01. | XOMA Corp (XOMA) Reports Statistically Significant Data from Gevokizumab Phase 2 | 12 | StreetInsider.com | |
| 07.01. | XOMA Offers Encouraging Interim Results from Gevokizumab Phase 2 Study | 6 | Benzinga.com | |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| ANTISOMA | 0,018 | +5,88 % | Antisoma PLC: TR1 Notification of major interest in shares |
| MEDIGENE | 0,922 | +3,71 % | Medigene: Rating wird erneuert |
| WILEX | 1,44 | +0,70 % | DGAP-HV: Wilex AG: Bekanntmachung der Einberufung -3- |
| AGENNIX | 0,06 | -37,5 % | Agennix AG gibt Liquidation bekannt |
| EVOTEC | 2,779 | +0,47 % | Evotec-Aktie: Jetzt einsteigen! |
